Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, has announced a significant milestone in the development of its potential breakthrough drug for Multiple Sclerosis (MS). The company has received the final reports for two critical studies— a 90-day oral toxicity study and a toxicokinetic study—on its lead compound, Lucid-21-302 (“Lucid-MS”). These reports will play a pivotal role in supporting Quantum BioPharma’s Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial.
Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the importance of this achievement: “We are pleased that we now have the final reports for these toxicity studies, as this represents an important milestone. These reports will be used to support Quantum’s IND application to the US FDA, further advancing the Lucid-MS drug development program.”
Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma, added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final reports, we move significantly closer to initiating our Phase 2 trial of Lucid-MS in people with Multiple Sclerosis.”
About Lucid-MS
Lucid-MS is a patented new chemical entity developed by Quantum BioPharma’s wholly owned subsidiary, Lucid Psycheceuticals Inc. The compound has demonstrated the ability to prevent and reverse myelin degradation—the underlying mechanism of Multiple Sclerosis—in preclinical models. If successful, Lucid-MS could become a groundbreaking treatment for MS, offering hope to millions of patients worldwide.
About Quantum BioPharma Ltd.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions targeting challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company’s drug candidates are at various stages of development, with Lucid-MS leading the charge.
In addition to its pharmaceutical endeavors, Quantum BioPharma has developed unbuzzd™, an over-the-counter product spun out to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc. (as of June 30, 2025) and benefits from a royalty agreement that includes 7% of sales until $250 million in payments are reached, after which royalties drop to 3% in perpetuity. The company also retains full rights to develop pharmaceutical and medical formulations of similar products.
Through its subsidiary, FSD Strategic Investments Inc., Quantum BioPharma also manages a portfolio of strategic investments secured by residential and commercial properties.
For more information, visit www.quantumbiopharma.com.
The post Quantum BioPharma Advances Multiple Sclerosis Drug Development with Key Study Reports appeared first on PRISM MarketView.
